StockData
AbbVie Inc. logo

AbbVie Inc.

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3089% above fair value
$288.84−6.05 (-2.05%)

Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%

AbbVie Eye Care Portfolio [folded into All Other in Q1 2026] by Quarter

Eye Care Portfolio [folded into All Other in Q1 2026] — Worldwide net revenues ($M) ($M)

QuarterlyAnnual

AbbVie Eye Care Portfolio [folded into All Other in Q1 2026]: $580M in Q4 2025, down 10.2% from a year earlier.

Latest, Q4 2025
580
Period ended Dec 31, 2025
Change on a year earlier
-10.2%
646 in Q4 2024
History
23 quarters
Since Q2 2020
Sources
23
Documents cited below

Where the Q4 2025 figure comes from

“|| Eye Care | 286 | 294 | 580 | (19.7) | 1.6 | (10.1) | (0.4) | (11.0)”

Source: Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗

Reported in Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Key Product Revenues.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedEye Care Portfolio [folded into All Other in Q1 2026] — Worldwide net revenues ($M) ($M)Year on yearSource
Q4 2025Dec 31, 2025580-10.2%Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗
Q3 2025Sep 30, 2025509-3.0%Form 8-K (abbv-20250930xexhibit991.htm, filed 2025-10-31) ↗
Q2 2025Jun 30, 2025514-3.6%Form 8-K (abbv-20250630xexhibit991.htm, filed 2025-07-31) ↗
Q1 2025Mar 31, 2025506-5.9%Form 8-K (abbv-20250331xexhibit991.htm, filed 2025-04-25) ↗
Q4 2024Dec 31, 2024646+10.4%Form 8-K (abbv-20241231xexhibit991.htm, filed 2025-01-31) ↗
Q3 2024Sep 30, 2024525-13.2%Form 8-K (abbv-20240930xexhibit991.htm, filed 2024-10-30) ↗
Q2 2024Jun 30, 2024533-13.6%Form 8-K (abbv-20240630xexhibit991.htm, filed 2024-07-25) ↗
Q1 2024Mar 31, 2024538-11.5%Form 8-K (abbv-20240331xexhibit991.htm, filed 2024-04-26) ↗
Q4 2023Dec 31, 2023585-0.8%Form 8-K (abbv-20231231xexhibit991.htm, filed 2024-02-02) ↗
Q3 2023Sep 30, 2023605-2.9%Form 8-K (abbv-20230930xexhibit991.htm, filed 2023-10-27) ↗
Q2 2023Jun 30, 2023617-13.9%Form 8-K (abbv-20230630xexhibit991.htm, filed 2023-07-27) ↗
Q1 2023Mar 31, 2023608-21.1%Form 8-K (abbv-20230331xexhibit991.htm, filed 2023-04-27) ↗
Q4 2022Dec 31, 2022590-38.5%Form 8-K (abbv-20221231xexhibit991.htm, filed 2023-02-09) ↗
Q3 2022Sep 30, 2022623-28.5%Form 8-K (abbv-20220930xexhibit991.htm, filed 2022-10-28) ↗
Q2 2022Jun 30, 2022717-22.0%Form 8-K (abbv-20220630xexhibit991.htm, filed 2022-07-29) ↗
Q1 2022Mar 31, 2022771-5.6%Form 8-K (abbv-20220331xexhibit991.htm, filed 2022-04-29) ↗

Breakdown

What makes up eye Care Portfolio [folded into All Other in Q1 2026]

Cite this data

StockData. (2026). AbbVie Eye Care Portfolio [folded into All Other in Q1 2026] ($M), quarterly Q2 2020–Q4 2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/ta-eye-ww

See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.